Literature DB >> 16168399

Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects.

Caroline Demacq1, Ana P de Souza, Alcyone A Machado, Raquel F Gerlach, Jose E Tanus-Santos.   

Abstract

BACKGROUND: Plasma MMP-9 levels have been shown to predict cardiovascular risk, and a functional substitution C to T at position -1562 in the promoter region of the MMP-9 gene has been associated with the severity of cardiovascular diseases. We examined the association between the C(-1562)T polymorphism and MMP-9 activity in healthy subjects.
METHODS: We studied 200 healthy male white volunteers (age range: 20-55 y) who were nonsmokers and were not taking medicines. Genomic DNA was extracted and genotypes for the C(-1562)T polymorphism were determined by PCR and restriction fragment length digestion. Plasma was assayed for pro-MMP-9 and MMP-9 activities by gelatin zymography.
RESULTS: The frequency of the alleles "C" and "T" were 90% and 10%, respectively. Because of the relatively low frequency of the TT genotype, we combined both TT and CT genotypes together (CT+TT group) and compared with the CC genotype group. We found no differences in pro-MM9 and MMP-9 activity levels among the genotype groups (both P>0.05).
CONCLUSIONS: While the present study indicates lack of effect for the C(-1562)T polymorphism on MMP-9 activity in plasma, it is possible that the C(-1562)T polymorphism contributes to an increased cardiovascular risk under conditions of induced MMP-9 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168399     DOI: 10.1016/j.cca.2005.08.017

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  MMPs as therapeutic targets--still a viable option?

Authors:  Barbara Fingleton
Journal:  Semin Cell Dev Biol       Date:  2007-07-06       Impact factor: 7.727

2.  Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity.

Authors:  Vanessa A Belo; Marcelo R Luizon; Patrícia C Carneiro; Valéria A Gomes; Riccardo Lacchini; Carla M M Lanna; Debora C Souza-Costa; Jose E Tanus-Santos
Journal:  Mol Biol Rep       Date:  2012-12-16       Impact factor: 2.316

Review 3.  Association of matrix metalloproteinase-9 C1562T polymorphism and coronary artery disease: a meta-analysis.

Authors:  Xiao Wang; Lei-zhi Shi
Journal:  J Zhejiang Univ Sci B       Date:  2014-03       Impact factor: 3.066

4.  Matrix Metalloproteinase-9 Level and Gene Polymorphism in Sleep Disordered Breathing Patients with or without Cardiovascular Disorders.

Authors:  Meral Yüksel; Hacer Kuzu-Okur; Ayliz Velioğlu-Öğünç; Zerrin Pelin
Journal:  Balkan Med J       Date:  2012-10-08       Impact factor: 2.021

5.  Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer.

Authors:  F J G M Kubben; C F M Sier; M J W Meijer; M van den Berg; J J van der Reijden; G Griffioen; C J H van de Velde; C B H W Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  2006-08-29       Impact factor: 7.640

6.  Gene Polymorphism of Matrix Metalloproteinase 9 in Asthenozoospermic Male Subjects.

Authors:  Sina Mohagheghi; Iraj Khodadadi; Manoochehr Karami; Iraj Amiri; Heidar Tavilani
Journal:  Int J Fertil Steril       Date:  2017-10-12

7.  Matrix Metalloproteinase-9 Is a Predictive Factor for Systematic Hypertension and Heart Dysfunction in Patients with Obstructive Sleep Apnea Syndrome.

Authors:  Shuhui Wang; Shisheng Li; Bin Wang; Jiajia Liu; Qinglai Tang
Journal:  Biomed Res Int       Date:  2018-03-06       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.